Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. The candidate fell short in a phase 2 psoriasis trial, prompting the French drugmaker to pull back from plans to develop ...

A Danish registry analysis identified demographic and biochemical factors linked to primary nonresponse and loss of response to anti-TNF therapy.

Patients with axial spondyloarthritis (axSpA) treated with tumor necrosis factor (TNF) inhibitors were at significantly lower risk for hip and spine fractures compared with those receiving only ...

Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with axial SpA treated with TNF inhibitors had ...

“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...

Please provide your email address to receive an email when new articles are posted on . Use of a second anti-TNF — IV or subcutaneous agent — resulted in early response and long-term remission among ...

If you have ankylosing spondylitis (AS), you might have heard of tumor necrosis factor (TNF). It’s a type of protein in your body that causes inflammation. If your immune system goes into overdrive ...